Brain metabolism is exquisitely responsive to activation or inhibition of brain activity, including activation or inhibition of receptors. By multivariate statistical analysis of the metabolic labelling patterns produced following one hour incubation with [3-
Brain metabolism is exquisitely responsive to brain activity with established relationships between glutamatergic activity and metabolic rates in the brain [2, 3] . The relationship in the case of GABAergic activity is less clear, with increases or decreases in energy metabolism being possible, depending on the net balance between the increase required by the move away from resting state membrane potential to hyperpolarization, and the resultant overall decrease in activity caused by inhibition of other cells [4] .
There are multiple metabolic compartments in the brain; these are classically divided into neuronal and glial compartments but in fact there are multiple subcompartments both in astrocytes and neurons [5] [6] [7] . This metabolic compartmentation means that activation of receptors whose localization is restricted in some RESEARCH HIGHLIGHT manner, such as to a particular population of neurons or to a particular extrasynaptic location, can invoke a unique metabolic response derived from the preferential perturbation of the metabolic (sub) compartments most influenced by (a) particular receptor(s).
Using the stable isotope 13 C, supplied as [3-13 C]pyruvate, it is possible to sample these unique metabolic responses. By allowing brain cortical tissue slices to metabolise [3- 13 C]pyruvate for a set period of time under exposure to ligands active at particular receptors or transporters one can obtain a metabolic "fingerprint" of activity evoked by that ligand, relative to metabolic activity in the absence of ligand. If one obtains enough of these fingerprints, a comprehensive picture of types of metabolic activity can be constructed.
For example, we have been constructing a metabolic picture of the GABAergic system. Our GABAergic "footprint" is a multivariate statistical analysis of the fingerprints generated by 43 different ligands known to be active in the GABAergic system, including agonists and antagonists at GABA(A), GABA(B), GABA(A)rho receptors, and the GABA transporters GATs1-3 and the betaine/GABA transporter BGT.
We used this footprint to identify candidate receptors at which the party drug γ-hydroxybutyrate (GHB) might be active [8] . One of these candidate receptors was subsequently independently verified [9] . These findings are consistent with very high degree of reliability and veracity of the metabolomics approach that we have developed for identifying unknown drug targets [10] . Moreover, the metabolomic approach -examining drug actions on brain tissue with much of its structural and functional integrity intact and a spectrum of potential pharmacological targets still in situ -could provide a vital link between the understandings of what the drugs does at a single type of receptor studied in vitro and its actual effects on brain function in vivo. This was our [1] . guiding principle when we recently used the footprint to examine the possible effects of ethanol in the GABAergic system [1] .
Ethanol is known to be a neuromodulatory agent with actions at a range of membrane proteins including GABA receptors. The most abundant synaptic GABA(A) receptors (mainly comprising α1, 2 and γ2 subunits) are, for practical purposes, non-responsive to ethanol [11] while those containing α4β3δ (and α6 in cerebellum) are about as ethanol-sensitive as N-methyl-D-aspartate receptors (except for being activated rather than inhibited by ethanol [12] ; see also [13, 14] ). Ethanol has biphasic outcomes [15] both with stimulatory and "relaxing" effects reported at low concentrations.
In addition, it has also been speculated that ethanol acts as a substrate in the brain, due to the significant reduction in glucose metabolism that is consequent on ethanol consumption. While ethanol itself may not be metabolized in brain to any degree, it has been speculated that acetate, produced following metabolism of ethanol in liver, may substitute as a brain substrate [16] . This question is a problematic one to answer in vivo, due to the effects of peripheral metabolism and the subsequent difficulty in determining the source of metabolites found in the brain. In contrast, the cortical tissue slice offers a useful alternative system in which to study effects of ethanol without peripheral interference, and without production of acetate from added ethanol. Acetate is known to be a poor substrate for metabolism in brain, due in part to its low ΔG [17] , and the distinct possibility of metabolism of acetate being blocked by acetylation of acetylCoA synthetase [18] . These data generated a three component model accounting for 82% of the variance in the data (47, 26 and 9%, respectively), the major two components of which are shown in this diagram. Ethanol data are shown as red circles, DS2 and etomidate as black squares, RO15-4513 and RO19-4603 as blue diamonds, Gabapentin as pink squares, tiagabine as purple squares, diazepam as green diamonds, QH-ii-066 as blue triangles, Zolpidem as orange squares and baclofen as green squares. All other data are represented as grey squares. The large outer ellipse represents the 95% confidence interval (Hotelling score). The inset to the figure shows an enlargement of the area of the PCA plot immediately surrounding the low (0.1 mM) concentration of ethanol. Key T, 10 µM tiagabine; Th, 10 µM THIP; iG, 10 µM isoguvacine; S, 10 µM SGS-742; AV, 100 µM vigabatrin with 5 µM AMPA; z, 40 nM zolpidem; C, 2 µM CI966; L, 0.1 nM L655-708; AVS 100 µM vigabatrin + 5 µM AMPA + 10 µM SKF-89976A; P, picrotoxin. Reprinted with permission [1] .
Using the cortical tissue slice model it has been shown that ethanol has distinct and significant effects on incorporation of 13 C-label into metabolites of the Krebs cycle and related amino acids, as well as on total metabolite pool sizes [1] . The high concentrations of ethanol used (10, 30 and 60 mM) were found to induce similar metabolic patterns and these patterns were shown to cluster on the GABAergic footprint with those from DS2(4-Chloro-N-[2-(2-thienyl)imidazo[1,2a]-pyridin-3-yl]benzamide), a positive allosteric modulator of α4β3δ-containing GABA(A) receptors, suggesting that these concentrations of ethanol act to reduce glucose metabolism directly via action as these receptors. Interestingly, the very low concentration of ethanolthat was used (0.1 mM) produced a quite different metabolic profile which clustered with those from inhibitors of GABA uptake, and ligands showing affinity for α5, and to a lesser extent, α1-containing GABA(A)R. Ethanol is known to have a biphasic effect and we suggest that the stimulatory effect of ethanol is modulated by these low concentrations of ethanol, equating to a single sip of wine.
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